Overview
Balance Sheet
Cash Flow
Growth Analysis
2024
2023
2022
2021
2020
Profitability Metrics
Gross Margin
29.72%
Operating Margin
15.63%
Net Margin
10.73%
Efficiency Metrics
Revenue per Expense Ratio
1.19
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
23.14%
Income Tax Rate
20.44%
EPS
5.9300000000
Balance Sheet Analysis
Current Ratio
1.08
Cash Ratio
0.21
Working Capital
$119.10M
Debt to Equity
1.65
Debt to Assets
43.40%
Equity Ratio
26.31%
Cash Flow Analysis
Operating Cash Flow Ratio
16.23%
Free Cash Flow Ratio
14.50%
CapEx to Revenue
1.74%
Dividends Paid
$368.20M
Stock Buybacks
$485.40M
Total Shareholder Returns
$853.60M
Cash Position Change
20.65%
Key Takeaways (2024 FY)
Maintained positive net income growth despite revenue changes
Increased dividend payments by 11.24%
Detailed Growth Metrics
Core Performance
Revenue
7.36%
Net Income
10.70%
EPS
10.63%
Operating Income
8.62%
Operational Efficiency
R&D Expenses
0.00%
SG&A Expenses
7.99%
Operating Cash Flow
28.29%
Free Cash Flow
26.08%
Balance Sheet Health
Assets
0.11%
Debt
4.80%
Book Value per Share
-3.23%
Inventory
-10.56%
Shareholder Returns
Dividends per Share
11.24%
Shares Outstanding
0.00%
Long Term Trends
3Y Revenue/Share
28.09%
5Y Revenue/Share
46.88%
3Y Dividend/Share
38.30%
5Y Dividend/Share
71.67%